Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma

PHASE1,PHASE2

Phase

TERMINATED

Status

Enrollment

NIH

Sponsor class

Stopped The pharmaceutical company discontinued availability of the drug and we were forced to close the study before phase II was completed. Only one participant was enrolled on phase II.

Conditions

Rhabdomyosarcoma
Rhabdomyosarcoma, Alveolar
Rhabdomyosarcoma, Embryonal

Interventions

DRUG: Dasatinib
DRUG: Dasatinib
DRUG: Ganitumab

Sponsor

National Cancer Institute (NCI)